Our Posts

Howmedica Osteonics and Stryker Corporation face a lawsuit over a defective hip implant. A federal judge allowed a strict liability manufacturing defect claim to proceed, as the Stryker Gamma 3 Nail System broke after normal use, leading to further surgeries and infection for the plaintiff. Other claims were dismissed. Stryker has faced multiple lawsuits and recalls, including a $1.4 billion settlement for defective hip implants. Parker Waichman LLP offers legal assistance for those affected by Stryker hip devices.

The Kugel Mesh Hernia Patch, initially praised for hernia treatment, was recalled due to serious risks, including bowel perforations. Despite the FDA's Class I recall, which indicates a severe danger, seven patients at two Virginia hospitals received the defective patches. One patient, Judith Coyne, suffers from severe pain and fears for her life due to the patch. Sentara Health Systems admitted the error, attributing it to confusion from the recall's phased approach. They are notifying affected patients and offering assistance. Legal help is available for those impacted.

Invokana, a diabetes drug manufactured by Janssen Pharmaceuticals, is linked to severe side effects, including lower limb amputations, leading to numerous lawsuits in the U.S. The FDA issued warnings about these risks, but many patients were affected before these warnings were publicized. Legal claims against Janssen and its parent company, Johnson & Johnson, focus on failure to warn and inadequate testing. Most cases are consolidated in New Jersey Federal Court under Multi-District Litigation. Parker Waichman LLP is actively representing affected individuals to seek damages.

Parker Waichman LLP offers legal assistance for injuries or fatalities related to St. Jude defibrillators. With extensive experience in handling cases involving defective medical devices, the firm has recovered over $2 billion for clients through verdicts and settlements. They provide a free case analysis with experienced lawyers specializing in St. Jude Implantable Cardiac Defibrillator Pacemaker lawsuits. Contact them for support and guidance in pursuing compensation.

Nationwide lawsuits are being filed against manufacturers of hernia mesh patches, including Johnson & Johnson and C.R. Bard, due to severe medical complications. Parker Waichman LLP, a national personal injury law firm, offers experienced hernia mesh lawyers to help victims secure compensation. The firm has a successful track record in representing clients harmed by defective medical devices. Manufacturers must ensure their products are safe and inform users of any risks. If injured, victims can seek justice and compensation through a free consultation with the firm.

Plaintiffs' attorneys in the Xarelto litigation allege that Bayer and Johnson & Johnson deceived medical journal editors by omitting crucial lab data in a letter published by Duke University researchers in The New England Journal of Medicine. This data, related to a clinical trial for Xarelto, was not disclosed despite being presented to regulators. The FDA approved Xarelto based on a trial with a faulty device, raising concerns about skewed results. Critics argue that the omission of lab data is an ethical breach, highlighting pharmaceutical influence on medical publications.

The U.S. Food and Drug Administration issued a Drug Safety Communication on May 16, 2017, confirming an increased risk of leg and foot amputations associated with the diabetes medication canagliflozin (Invokana, Invokamet, and Invokamet XR). This decision was based on findings from two clinical trials, CANVAS and CANVAS-R. The CANVAS study assessed the cardiovascular safety of canagliflozin, while CANVAS-R focused on its effects on renal endpoints. Both studies highlighted the elevated risk of amputations, leading to updated warning labels for these medications.

Purdue Pharma, the maker of OxyContin, is involved in a lawsuit due to its role in the opioid crisis. The company is accused of misrepresenting the risks of its drugs, contributing to widespread addiction and overdoses. A settlement is being negotiated, with Purdue Pharma agreeing to pay billions after filing for bankruptcy. Those affected by opioid addiction or related issues may be eligible for compensation. The lawsuit covers various Purdue Pharma drugs, and eligibility requires having suffered specific consequences from their use. Legal assistance is available for those seeking compensation.

DePuy Orthopaedics and Johnson & Johnson face numerous lawsuits over their recalled DePuy ASR metal-on-metal hip implants, which allegedly caused injuries like metal poisoning and implant failure. The ASR systems were globally recalled in 2010 due to high failure rates. Parker Waichman LLP represents many clients in these cases, including a recent lawsuit from a South Carolina couple. The lawsuits claim the implants' design is defective and that the companies failed to warn about the risks. DePuy has allocated $2.5 billion for settlements and faces additional legal actions over the Pinnacle hip implant.

The Kugel Mesh Hernia Patch multidistrict litigation (MDL) is set to begin its first trial, serving as a bellwether for hundreds of similar cases. John Whitfield of Missouri claims the patch's rings broke, causing severe complications, and accuses Davol Inc. and C.R. Bard, Inc. of negligence. Initially praised, the patch faced failures, leading to a Class I recall by the FDA due to serious risks. Over 1,500 lawsuits are pending in the MDL, with additional cases in Rhode Island Superior Court.

Judge Eldon Fallon has extended the filing deadline for certain plaintiffs in the Xarelto Products Liability Litigation, MDL #2592. The litigation involves claims against Janssen Pharmaceuticals, Johnson & Johnson, and Bayer for allegedly failing to warn about Xarelto's risks of uncontrollable bleeding. Despite FDA approval in 2011, many patients reported severe side effects. Investigations revealed potential misleading marketing and defective clinical trial devices. Xarelto, endorsed by celebrities, achieved nearly $2 billion in U.S. sales, becoming a leading alternative to warfarin.

An article by *Health Imaging* highlights concerns about MRI dyes, specifically gadolinium-based contrast agents (GBCAs). German researchers found that gadodiamide, a linear gadolinium-based dye, leaves significant gadolinium deposits in rats' brains, while gadoterate, a macrocyclic dye, leaves only trace amounts. The FDA acknowledges gadolinium retention but has not linked it to adverse effects in patients with normal kidney function. However, there is a potential risk for those with impaired kidney function. The FDA requires a Medication Guide for patients and mandates further studies on GBCAs.

On June 1, 2022, the FDA withdrew approval for Ukoniq (umbralisib), a cancer drug used to treat marginal zone lymphoma and follicular lymphoma, due to safety concerns. The decision followed findings from the UNITY-CLL clinical trial, which indicated an increased risk of death in patients using Ukoniq. TG Therapeutics, the manufacturer, voluntarily withdrew the drug from the market. The FDA advised healthcare professionals to stop prescribing Ukoniq and recommended patients switch to alternative treatments. Parker Waichman LLP is investigating potential claims against the drug's manufacturer.

Covidien, now Medtronic, faces lawsuits over its hernia mesh products, which are alleged to cause severe injuries due to defective design and inadequate warnings. These products, made from synthetic materials, have led to complications such as chronic pain, infections, and bowel obstructions, often requiring additional surgeries. Parker Waichman LLP is actively pursuing these cases and offers free consultations to affected individuals. While Covidien has settled pelvic mesh cases, hernia mesh settlements are pending. Legal actions aim to secure compensation for medical costs, lost wages, and other damages.

Taxotere, a chemotherapy drug by Sanofi-Aventis, is effective in treating breast cancer but has been linked to permanent hair loss, or alopecia. Lawsuits claim Sanofi failed to disclose this side effect, which affects all body hair. Studies indicate a significant percentage of patients experience long-term hair loss. Despite awareness of this risk in Canada and Europe, the U.S. label was only updated recently. The FDA previously criticized Sanofi for misleading efficacy claims. Legal assistance is available for affected individuals.

Selecting the right lawyer for a Canagliflozin amputation lawsuit is crucial for those affected by Invokana. Parker Waichman LLP offers experienced legal counsel to hold manufacturers accountable for injuries. They are actively pursuing litigation against Janssen Pharmaceuticals and Johnson & Johnson, alleging negligence and misconduct. When choosing a lawyer, consider their experience with drug product cases, involvement in Invokana MDL, and communication process. Parker Waichman provides free consultations and has a strong track record in challenging large pharmaceutical companies, making them a reliable choice for Invokana claims.

The FDA has issued a warning about the HIV medication dolutegravir, highlighting its link to neural tube defects in infants when taken during early pregnancy. This warning follows a study in Botswana showing increased rates of such defects in babies exposed to the drug. Dolutegravir, an antiretroviral medication, is used to treat HIV by inhibiting the integrase enzyme. Pregnant women taking dolutegravir should consult their doctors before making any changes to their medication. Ongoing research continues to investigate these risks, and legal claims may arise if manufacturers failed to warn about potential dangers.

A popular epilepsy drug, topiramate (Topamax), has been linked to an increased risk of birth defects, specifically cleft lips and palates, when taken by pregnant women during the first trimester. Research indicates that women taking 100 mg of topiramate for non-epileptic reasons have a 50% higher risk of having a child with these defects. The risk is even greater for women with epilepsy taking 200 mg. Legal actions are being pursued against the manufacturer, Janssen Pharmaceuticals, for inadequate warnings about these risks.

Acute Myeloid Leukemia (AML) is a fast-progressing cancer of the bone marrow, characterized by the overproduction of abnormal myeloid cells. Enasidenib (Idhifa) is an oral medication used to treat AML patients with IDH2 mutations. It works by inhibiting the mutated IDH2 protein, helping to control cancer growth with fewer side effects. Common side effects include nausea and diarrhea, while severe ones like differentiation syndrome can occur. The FDA approved Enasidenib in 2017, emphasizing the need for careful monitoring of differentiation syndrome symptoms. Risk factors for AML include age, gender, and previous exposure to carcinogens.

Parker Waichman LLP represents victims of defective medical devices, specifically those affected by St. Jude Medical's cardiac resynchronization therapy defibrillators (CRT-Ds). These devices, with faulty lithium batteries, pose life-threatening risks as they can fail without warning, leading to severe health complications or death. The firm offers legal assistance to those impacted, including families of deceased individuals, to seek compensation. With extensive experience against major manufacturers, Parker Waichman LLP has recovered over $2 billion for clients. They provide free case reviews and ensure claims are filed within the statute of limitations.

The FDA has issued a safety notice regarding the risks of neurovascular stents used in stent-assisted coiling (SAC) for unruptured aneurysms, linking them to strokes and fatalities. Parker Waichman LLP is pursuing product liability claims to help affected individuals seek compensation. The firm emphasizes the importance of consulting an attorney to determine eligibility for a lawsuit and to navigate the legal process. They operate on a contingency fee basis, meaning clients pay only if the case is successful. Parker Waichman LLP has a strong track record, having recovered over $2 billion for clients.

Xarelto, manufactured by Janssen Pharmaceuticals and Bayer Corporation, is an anticoagulant designed to prevent excessive clotting and reduce the risk of strokes and embolisms. It offers convenience by eliminating the need for regular blood monitoring and dietary restrictions. Xarelto is used to prevent strokes in patients with atrial fibrillation, treat and reduce recurrence of deep vein thrombosis (DVT), prevent pulmonary embolism (PE), and prevent blood clots post knee or hip replacement surgery. Discussing potential risks with a healthcare professional is advised.

Hundreds of women have filed lawsuits against Bayer Pharma AG, claiming that the Mirena intrauterine device (IUD) caused serious health complications, including uterine perforation, device migration, and other side effects. The plaintiffs argue that Bayer failed to adequately warn about these risks. Bayer denies any wrongdoing, citing studies supporting the device's safety. Despite the lawsuits, courts have ruled in favor of Bayer. The litigation continues, with potential for new evidence to impact future cases. Parker Waichman LLP represents many of the affected women, advocating for their rights and seeking compensation.

Actemra lawsuits are being filed due to serious side effects like heart attacks and strokes. Parker Waichman LLP is representing affected individuals, offering legal assistance to secure compensation for medical bills, lost wages, and suffering. Actemra, manufactured by Roche/Genentech, was marketed as safer than other arthritis treatments but has similar risks. To pursue a claim, prove the link between Actemra and your injury, and act within the statute of limitations. Contact Parker Waichman LLP for legal support and to understand your rights.